Dataset Information

Myokines in gastric cancer cachexia

ABSTRACT: In this study, we sought to explore the importance of selected myokines in a homogenous population of patients with gastric cancer characterized by high rates of Cancer-Associated Cachexia [CAC]. Myokine levels in peripheral blood were compared between patients with and without cachexia to identify mediators potentially involved in the pathogenesis of CAC. Moreover, we compared myokine concentrations in paired samples of portal and peripheral blood to verify whether they are released by the primary tumour. Finally, a label-free quantitative proteomics was applied to explore other potential circulating mediators of CAC and to analyse their interactions with myokines.

INSTRUMENT(S): maXis

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

DISEASE(S): Gastric Adenocarcinoma

SUBMITTER: Anna Drabik

LAB HEAD: Anna DRABIK

PROVIDER: PXD049334 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	100.2_E7_01_22987.d.rar	Other
	100.3_A3_01_23035.d.rar	Other
	100.4_A3_01_23084.d.rar	Other
	100.5_C7_01_23145.d.rar	Other
	101.2_F1_01_22995.d.rar	Other

Items per page:

1 - 5 of 66

Publications

Dissecting the importance and origin of circulating myokines in gastric cancer cachexia.

Sierzega Marek M Drabik Anna A Sanak Marek M Chrzan Robert R Richter Piotr P

Frontiers in endocrinology 20241001

<h4>Background</h4>Some experimental data suggest that myokines may play an important role in developing cancer-associated cachexia (CAC), but their relevance in humans remains poorly explored. In our study, we tested the hypothesis that circulating myokines are associated with the pathogenesis of CAC in a model population of gastric cancer.<h4>Methods</h4>A group of 171 treatment naïve patients with adenocarcinoma of the stomach were prospectively examined. Cachexia was defined as weight loss > ...[more]

PMID: 39411315

Similar Datasets

Project description:Background: Cancer cachexia (CAC) reduces patient survival and quality of life. Developments of efficient therapeutic strategies are required for the CAC treatments. This long-term process could be shortened by the drug-repositioning approach which exploits old drugs approved for non-cachexia disease. Amiloride, a diuretic drug, is clinically used for treatments of hypertension and edema due to heart failure. Here, we explored the effects of amiloride for ameliorating muscle wasting in murine models of cancer cachexia. Methods: CT26 and LLC tumor cells were subcutaneously injected into mice to induce cancer cachexia. Amiloride was intraperitoneally injected daily once tumors were formed. Cachexia features of the CT26 and LLC models, respectively, were characterized by phenotypic, histopathologic and biochemical analyses. Plasma exosomes and muscle atrophy-related proteins were quantitatively analyzed. Integrative NMR-based metabolomic and transcriptomic analyses were conducted to identify significantly altered metabolic pathways and distinctly changed metabolism-related biological processes in gastrocnemius. Results: The CT26 and LLC models displayed prominent cachexia features including decreases in body weight, skeletal muscle, adipose tissue and muscle strength. The amiloride treatment in tumor-bearing mice distinctly alleviated muscle atrophy and relieved cachexia-related features without affecting tumor growth. The CT26 and LLC cachexia mice showed increased particle density of plasma exosomes which were largely derived from tumors. Significantly, the amiloride treatment inhibited tumor-derived exosome release, which did not obviously affect exosome secretion from non-neoplastic tissues or induce observable systemic toxicities in normal healthy mice. Integrative-omics revealed significant metabolic impairments in cachectic gastrocnemius, including promoted muscular catabolism, inhibited muscular protein synthesis, blocked glycolysis and impeded ketone body oxidation. The amiloride treatment evidently improved the metabolic impairments in cachectic gastrocnemius. Conclusions: Our results demonstrated the efficacy of amiloride in ameliorating cachectic muscle wasting and elucidated the underlying mechanistic rationale for its use as an alternative strategy to improve CAC treatments.